FSH Test and Antral Follicle Count: The Ovarian Reserve Tests Beyond AMH

The clip runs twelve seconds. A woman holds a lab printout to the camera, points at one number and announces that she has “maybe three fertile years left.” The number is her FSH. As of October 2025, variations of that video, plus a wave of mail-order hormone panels, have pushed the fsh test back into the search charts, often alongside a second phrase people had never typed before: antral follicle count.

It is an odd comeback. For a decade, clinics have leaned on AMH, the anti-Mullerian hormone made by small follicles, as the headline marker of ovarian reserve. FSH was the older, fussier test, tied to a cycle day and prone to bouncing around. Now it is trending again, partly because at-home kits measure it, partly because people want a second opinion on an AMH result that frightened them.

Here is what those two older tests can actually tell you, where the viral claims overreach, and why no single number deserves the power the videos give it.

What does FSH stand for, and what does an FSH test measure?

FSH stands for follicle-stimulating hormone. It is made by the pituitary, a pea-sized gland at the base of the brain, and its job is exactly what the name says: it stimulates follicles, the fluid-filled sacs in the ovary that each hold an immature egg. In the first days of a menstrual cycle, FSH rises, a cohort of follicles responds, and usually one wins the race to ovulation.

An FSH test is a blood draw that measures how much of that hormone is circulating at one moment. The result is reported in international units per litre (IU/L) or milli-international units per millilitre (mIU/mL); the two are numerically identical, so a 7 in one unit is a 7 in the other.

The test is not a fertility score. It is a readout of a conversation between the brain and the ovaries. When the ovaries are well stocked with follicles, they produce enough estrogen and a related hormone, inhibin B, to tell the pituitary to ease off. When the stock thins, that feedback weakens and the pituitary shouts louder. A raised early-cycle FSH is the sound of the pituitary shouting.

Clinicians order the test for several reasons: to help evaluate difficulty conceiving, to investigate irregular or absent periods, to look into early menopause or primary ovarian insufficiency, to assess delayed or early puberty, and, in men, to help explain a low sperm count. The same hormone, the same tube of blood, but very different questions, which is why the number only makes sense next to the reason it was drawn.

In this article the focus is the ovarian reserve question, because that is the use driving the current surge of interest, and the use most often misread.

Why FSH rises as the ovaries slow down

Picture the pituitary as a thermostat and the ovaries as the furnace. The thermostat sends a signal (FSH), the furnace produces heat (estrogen and inhibin B), and the heat tells the thermostat to stop calling. A young ovary with thousands of small follicles responds quickly, so the thermostat barely has to click on. Baseline FSH stays low, typically in the single digits.

Egg supply is finite and declines from before birth. A fetus carries several million oocytes; by puberty perhaps 300,000 to 400,000 remain; by the late 30s the pool has dropped sharply, and the rate of loss accelerates. As the pool shrinks, fewer small follicles grow each month, less inhibin B is made, and the brake on the pituitary loosens. FSH creeps upward, cycle by cycle, long before periods become irregular.

This is why an early-cycle FSH measurement can hint at ovarian reserve: the hormone is a mirror held up to the follicles. It is also why the mirror is imperfect. The feedback loop has a lag, and the ovary can have a good month and a bad month. A dominant follicle left over from a previous cycle, a cyst, or simple biological noise can push one reading down and the next one up.

Two further points matter. First, FSH reflects quantity, the number of follicles available, not the chromosomal quality of the eggs inside them, which tracks mainly with age. Second, a single normal FSH does not reset the clock. A 42-year-old with a textbook FSH still has 42-year-old eggs. The hormone tells you how hard the pituitary is working, not how old the eggs are.

When should FSH be tested? Timing is everything

For ovarian reserve, the FSH test is usually drawn on day 2, 3 or 4 of the menstrual cycle, counting the first day of full flow as day 1. This window is called “basal” or “baseline” FSH, and the timing is not fussiness for its own sake. Estrogen from a growing follicle suppresses FSH, so a reading taken mid-cycle or just before a period can look reassuringly low for the wrong reason. Early in the cycle, before any follicle has taken the lead, the pituitary’s true baseline effort shows.

Many clinicians order estradiol, the main form of estrogen, from the same tube. A normal FSH alongside a high early estradiol is a flag: the estrogen may be masking an FSH that would otherwise be raised. Reading one without the other is like judging a thermostat without knowing the room temperature.

Timing matters less when the question is different. If periods have stopped altogether and menopause or primary ovarian insufficiency is suspected, there is no cycle day to wait for, and repeat samples a few weeks apart are more informative than one. For irregular cycles, a clinician may simply test on the first available day and interpret cautiously, or lean on AMH and antral follicle count, which do not depend on cycle day.

Several things distort the result and are worth mentioning before the draw: combined hormonal contraception and other hormonal treatments suppress FSH; recent pregnancy or breastfeeding alters it; high-dose biotin supplements can interfere with some laboratory assays; and a fertility medication cycle changes everything. Men can be tested on any day.

The practical rule: the FSH number is only as good as the day it was drawn and the hormones that were drawn beside it. A result with no cycle day attached is a result without context.

What do FSH test results mean? Reading the number honestly

Laboratories set their own reference ranges, so the figures below are typical rather than universal, and the printout from your own lab wins any disagreement.

• In the early follicular phase (days 2–5), most laboratories place the premenopausal range roughly between 3 and 10 IU/L, with some extending the upper limit a little higher.
• Around ovulation, FSH spikes briefly as part of the mid-cycle surge, so a reading from that window is not comparable.
• After menopause, with no follicles left to answer, FSH typically sits above 25 to 30 IU/L and often well beyond.

In fertility practice, a basal FSH that is persistently raised, in the high single digits or above 10 IU/L depending on the assay, is taken as a sign of diminished ovarian reserve: fewer follicles likely to respond to stimulation. UK guidance, for example, has used a threshold around 9 IU/L to flag a probable low response to fertility medication. That is a statement about how the ovaries might behave in a treatment cycle, not a verdict on natural conception.

Variability deserves a blunt sentence. FSH can differ by several units from one cycle to the next in the same person, especially in the late 30s and 40s. One high value is a prompt to repeat and to add other markers, not a diagnosis. Clinicians generally weight the highest value ever recorded more than a later lower one, because the ovary does not regain follicles, but even that rule is applied with judgment.

A low FSH is a different story. In someone with absent periods, a low or low-normal FSH points away from the ovaries and toward the brain or pituitary: hypothalamic suppression from low energy availability, high prolactin, thyroid disease or, rarely, a pituitary problem. The same number, read against a different history, means something else entirely.

What is an antral follicle count, and how is it done?

An antral follicle count (AFC) is a transvaginal ultrasound in which the sonographer counts the small resting follicles, typically those measuring about 2 to 10 millimetres, visible in both ovaries. “Antral” refers to the fluid-filled cavity these follicles have developed; they are the ones close enough to the starting line to respond to FSH that month.

The scan takes a few minutes and is usually scheduled in the early follicular phase, the same days used for basal FSH, although AFC varies less across the cycle than FSH does and can be done on other days if needed. There is no blood draw and the result is immediate: a number, often reported for each ovary and as a total.

Why does it matter? Because the count of visible antral follicles is a reasonably direct window onto the much larger hidden pool of primordial follicles. Where FSH infers the state of the ovary from a hormone signal, AFC looks at the ovary itself. Studies comparing the two for predicting how many eggs will be retrieved in an IVF cycle consistently find AFC and AMH perform similarly and both outperform FSH.

Broad interpretive bands used in fertility clinics look like this: a total count below roughly 5 to 7 suggests low reserve and a likely poor response to stimulation; a count in the teens is typical; a count above about 20 to 25 raises the possibility of polycystic ovaries and a higher risk of over-response to fertility drugs. Exact cut-offs differ between clinics and ultrasound machines.

The method has limits. It depends on the operator’s skill and the equipment, counts can differ between sonographers, and obesity, ovarian cysts or previous ovarian surgery can make follicles harder to see. Hormonal contraception also lowers the visible count. Like FSH, AFC speaks to quantity rather than quality.

FSH test vs AMH vs antral follicle count: how the three compare

Each marker approaches the same question from a different angle, and a good fertility assessment usually orders at least two. The table summarises where each one is strong and where it wobbles.

Marker	What it measures	Cycle timing	Main strengths	Main limits
FSH (with estradiol)	Pituitary signal to the ovary; rises as reserve falls	Day 2–5 of cycle	Inexpensive, widely available, useful for menopause and primary ovarian insufficiency	Varies cycle to cycle; masked by high estradiol; rises late in the decline
AMH	Hormone released by small growing follicles	Any day	Stable across the cycle; best single blood predictor of IVF egg yield	Lowered by hormonal contraception; assay differences; does not predict natural conception
Antral follicle count	Ultrasound count of 2–10 mm follicles	Preferably day 2–5	Direct view of the ovary; predicts IVF response as well as AMH; also flags polycystic ovaries	Operator and machine dependent; needs a transvaginal scan; harder with cysts or prior surgery

A few patterns emerge. FSH is the oldest and cheapest, and it remains the test of choice when the question is menopause rather than reserve. AMH and AFC are the better tools for predicting how the ovaries will respond to stimulation, which is why fertility clinics now lead with them. FSH tends to rise relatively late in the reserve decline, when AMH and AFC have already fallen, so a normal FSH is weaker reassurance than a normal AMH.

None of the three is a fertility test in the everyday sense. All three estimate how many eggs are available, and all three are silent on whether those eggs are chromosomally healthy, whether ovulation happens, whether the tubes are open or whether sperm are normal. That is the single most important thing to carry away from the comparison.

What changed recently: why the fsh test is back in the conversation

Nothing dramatic has happened to FSH chemistry. What has changed is how the test is reaching people and how the results are being interpreted in public.

The scientific backdrop was set in October 2017, when a prospective study of 750 women aged 30 to 44 with no history of infertility, published in JAMA and indexed on PubMed, followed participants for up to a year of trying to conceive. Women with a raised early-follicular FSH, or a low AMH, were no less likely to conceive within six or twelve cycles than women with normal values. That finding has been quoted in guidance ever since: ovarian reserve markers predict response to fertility treatment, not the chance of a spontaneous pregnancy.

Since then, two trends have collided. Direct-to-consumer hormone panels, including finger-prick FSH and AMH tests and urine FSH strips marketed for “menopause checking,” have become easy to buy and easy to post about. At the same time, short-form video has turned individual lab printouts into content, often stripped of the cycle day, the estradiol value and the clinical question that make a number meaningful.

Guidance from mainstream sources has stayed steady. MedlinePlus and Cleveland Clinic describe FSH as one piece of a fertility or menopause work-up; the NHS infertility pathway lists hormone blood tests alongside semen analysis, tubal assessment and ultrasound rather than as a stand-alone verdict; and Mayo Clinic notes that perimenopause is diagnosed mainly from age and symptoms, with hormone levels used selectively because they fluctuate.

So the honest summary of “what changed” is this: the evidence base has been reasonably settled for years, while the audience reading the results has widened enormously. That gap, more than any new trial, is why the fsh test deserves a clearer explanation now.

What the evidence actually says, graded by strength

It helps to separate what is well established from what is often asserted.

Strong, consistent evidence (large observational cohorts and meta-analyses): AMH and antral follicle count predict the number of eggs retrieved in an IVF cycle better than basal FSH, and all three are better than age alone for that purpose. This has been replicated across many clinics and is the reason stimulation protocols are tailored to these markers.

Strong evidence against a popular belief (prospective cohort data): In women without known infertility, raised FSH and low AMH do not meaningfully reduce the chance of conceiving naturally over six to twelve months. The 2017 JAMA cohort is the clearest example. The markers describe quantity; natural fertility depends more on egg quality, ovulation, tubes and sperm.

Moderate evidence (observational): Persistently raised FSH, particularly with an elevated early estradiol, is associated with a poorer response to stimulation and a higher cancellation rate in treatment cycles. The association holds, but the thresholds vary between laboratories and studies.

Expert consensus rather than trial data: Cycle-day timing for FSH, the practice of pairing it with estradiol, and the convention of weighting the highest recorded FSH all come from clinical experience and physiological reasoning, not randomised comparisons.

Weak or absent evidence: That any supplement, diet or lifestyle change lowers FSH in a way that restores ovarian reserve. Small studies exist for various products; none meets the bar of a well-powered randomised trial with a live-birth outcome.

Randomised trials of ovarian reserve testing itself are scarce, because the tests are diagnostic rather than therapeutic. The strongest evidence we have is therefore prognostic: it tells us what the numbers predict, and the most reliable prediction is about treatment response, not about the timeline of a family.

Normal FSH levels during perimenopause and menopause

Perimenopause is the transition, often several years long, during which the ovaries wind down and cycles become irregular before stopping. It is also the stage at which FSH becomes least predictable, which is exactly why people searching for a “normal perimenopause FSH” rarely get a satisfying answer.

During this transition FSH typically drifts above the premenopausal range, often into the teens or 20s IU/L, but it does not climb in a straight line. A value of 25 one month can be followed by 8 the next, because the ovary occasionally recruits a healthy follicle, estrogen rises, and the pituitary briefly stands down. Cleveland Clinic and Mayo Clinic both make the same practical point: hormone tests can support a diagnosis of perimenopause, but the diagnosis rests on age, symptoms and menstrual pattern, and a single result cannot confirm or rule it out.

After the final period, when FSH has stayed consistently elevated, commonly above 25 to 30 IU/L and frequently much higher, with low estradiol, the picture is clearer. Menopause itself is confirmed retrospectively, twelve months after the last period, rather than by a blood test.

Where FSH testing is genuinely useful in this age range:

• Under 40 with absent or infrequent periods, to assess for primary ovarian insufficiency, where two raised FSH results at least a month apart are a key part of the definition.
• Between 40 and 45 with menopausal symptoms and a changed cycle, where a clinician may test to support the diagnosis.
• After hysterectomy or on certain hormonal treatments, when menstrual pattern cannot be used as a guide.

The home urine kits that have fuelled part of this trend detect FSH above a fixed threshold. A positive strip means the hormone was high on that day; given the swings described above, it cannot by itself establish menopause or rule out pregnancy.

How can high FSH levels be treated in females?

The honest answer, and the one the viral videos skip, is that high FSH is a signal rather than a disease. The hormone is elevated because the ovary is sending less feedback. Lowering the number without changing the ovary would be like muffling a smoke alarm: quieter, not safer. There is no medicine that restores lost follicles, and no supplement with convincing randomised-trial evidence of doing so.

What clinicians can address is the situation behind the number, and the right approach depends on the goal.

If the goal is pregnancy: A raised FSH shifts the conversation toward timing and strategy. Options a fertility specialist may discuss include trying to conceive sooner rather than later, fertility treatment with stimulation protocols adjusted for an expected lower response, and, when reserve is very low, treatment using donor eggs, which carries success rates tied to the donor’s age rather than the recipient’s. Which path fits is a decision for the treating clinician, informed by age, AMH, antral follicle count, partner factors and personal priorities.

If the cause is primary ovarian insufficiency before 40: Mayo Clinic and other mainstream sources describe hormone replacement, usually estrogen with a progestogen, as a standard consideration to manage symptoms and protect bone and cardiovascular health until the typical age of menopause. This treats the consequences of low estrogen; it does not change the underlying reserve, and whether and how it is used is a prescribing decision.

If the context is natural perimenopause: Treatment, when wanted, targets symptoms such as hot flashes, sleep disruption or mood change, not the FSH value.

Across all three situations, lifestyle factors with evidence for general reproductive health, not smoking, a healthy weight and limiting alcohol, are sensible but should not be sold as ways to “fix” FSH. Anyone considering changing or stopping a prescribed hormone should discuss it with the prescriber first.

When a low or normal FSH is the real clue

Most of the attention goes to high values, yet in several common situations a low or deceptively normal FSH is the more important finding.

Polycystic ovary syndrome (PCOS): People with PCOS often have a normal FSH with a relatively high LH, luteinising hormone, the pituitary partner that triggers ovulation. The ratio, together with symptoms and an ultrasound showing many small follicles, points toward PCOS rather than low reserve. A high antral follicle count in this setting is not good news about fertility so much as a marker of disrupted ovulation and a warning about over-response to fertility medication.

Hypothalamic amenorrhea: When the body perceives an energy deficit, from intense training, restrictive eating or significant stress, the hypothalamus reduces the hormone that drives FSH and LH. Periods stop, and FSH is low or low-normal. The ovary is fine; the signal has been switched off upstream. Treatment focuses on the cause, and FSH testing is part of recognising it.

Masked FSH: A normal basal FSH beside an early-cycle estradiol that is already high can hide diminished reserve. A follicle has started early, estrogen has suppressed FSH, and the number looks healthier than the ovary is. This is why estradiol belongs on the same request form.

Hormonal contraception: Combined pills, patches, rings and some other hormonal methods suppress FSH and lower AMH and antral follicle count. Testing while on them tells you about the medication, not the ovary.

Pituitary and thyroid causes: High prolactin and untreated thyroid disease both disturb the axis and can produce low or unpredictable FSH with absent periods. Rarely, pituitary disease itself is responsible.

Each of these is a reason an FSH result needs a clinician’s eye rather than a chart on the internet. The number is the same; the meaning turns on everything around it.

Who should consider ovarian reserve testing, and who may not need it

Testing is most useful when the result will change a decision. That principle sorts people fairly cleanly.

Testing is generally reasonable for someone who has been trying to conceive for a year without success, or six months if over 35, because it sits naturally within the broader infertility work-up that NHS and Mayo Clinic describe: hormone tests, semen analysis, ultrasound and an assessment of the fallopian tubes. It makes sense before planned IVF or egg freezing, where FSH, AMH and antral follicle count guide the stimulation plan. It is appropriate for anyone under 40 with absent or very infrequent periods, where primary ovarian insufficiency must be considered, and for people who have had chemotherapy, pelvic radiotherapy or ovarian surgery, which can reduce reserve.

Where the value is weaker is the scenario the trend has created: a person in their 20s or early 30s, with regular cycles and no plans to conceive soon, ordering a panel to “check the clock.” The tests cannot forecast natural fertility in that group, a low result can cause distress without a clear next step, and a normal result can lull someone into assuming more time than age allows. Clinicians increasingly frame reserve testing as a treatment-planning tool rather than a screening test for the general population.

There is a middle group where testing can be helpful: those weighing egg freezing, those with a family history of early menopause, and those with conditions such as endometriosis that may affect the ovaries. In these cases the markers inform a real choice.

If testing is pursued, the interpretation should come from someone who can put the number beside the cycle day, the estradiol, the ultrasound and the history. A result delivered by a kit, without that context, is data without a clinician, and that is where most of the current confusion begins.

Common myths about the FSH test and ovarian reserve

The claims below circulate widely enough to deserve a direct correction.

“My FSH tells me how many fertile years I have left.” No test does this. FSH describes current reserve and current pituitary effort, with month-to-month variation. It cannot be converted into a countdown, and the 2017 JAMA cohort showed raised FSH did not reduce natural conception rates over a year.

“High FSH means I can’t get pregnant.” It means the ovary is responding less and fertility treatment may be harder. Natural conception still occurs with raised FSH, more often than the videos suggest, especially in younger women. The marker is about quantity; a single good egg is enough.

“Normal FSH means my fertility is fine.” FSH rises late in the decline and can be masked by estradiol. A normal value in a 41-year-old does not change the age of the eggs, the state of the tubes or a partner’s sperm count.

“AMH replaced FSH, so FSH is useless.” AMH and antral follicle count are better at predicting IVF response, but FSH remains the key test for menopause, primary ovarian insufficiency and for sorting ovarian from pituitary causes of absent periods.

“A positive home FSH strip confirms menopause.” It confirms FSH was above the strip’s threshold that day. During perimenopause the hormone swings widely, so a positive result can be followed by a normal one, and ovulation and pregnancy remain possible.

“Supplements can lower FSH and rebuild reserve.” Small or poorly controlled studies exist; none provides randomised evidence of more follicles or more live births. Lowering the number without changing the ovary has no benefit.

“Antral follicle count is objective, so it beats blood tests.” It is a direct view, but counts vary between operators and machines, and cysts, surgery or body habitus can obscure follicles. It is best read alongside AMH rather than instead of it.

Preparing for the test and what can skew the result

A few practical details make the difference between a usable FSH result and a confusing one.

Ask for the cycle day in advance. If the question is ovarian reserve, the draw should fall on day 2 to 4, and estradiol should be requested alongside. If periods are unpredictable, the clinician may ask for the sample on the first day flow starts, or substitute AMH and antral follicle count, which are less dependent on timing. No fasting is required.

Tell the ordering clinician about any hormonal medication, including combined or progestogen-only contraception, hormone replacement, fertility drugs and recent use of emergency contraception, and about pregnancy or breastfeeding in the previous year. All of these alter FSH, and some suppress it enough to make the test uninformative. The clinician may suggest a washout period or a different marker; stopping a prescribed medicine for a test is a decision to make with the prescriber, not alone.

Mention supplements, particularly high-dose biotin, sometimes sold for hair and nails, which can interfere with the immunoassays many laboratories use for FSH and related hormones. Mention thyroid disease and any medication that raises prolactin, because both can disturb the axis.

For an antral follicle count, the scan is transvaginal and takes a few minutes; an empty bladder is usually preferred. It is reasonable to ask whether the clinic reports the count per ovary and what range it uses, since cut-offs differ.

When the results arrive, resist comparing them with a stranger’s printout. The right comparison is with the laboratory’s own reference range, the cycle day, the estradiol, and, ideally, with AMH and the ultrasound. If a value is borderline or surprising, a repeat in a later cycle is standard and is not a sign that something has gone wrong.

When to see a doctor about FSH, antral follicle count or fertility concerns

Ovarian reserve testing is a conversation starter, not a conclusion, and some situations need a clinician promptly rather than another kit.

Book an appointment if:

• You are under 40 and periods have become infrequent or have stopped for three months or more without pregnancy, hormonal contraception or breastfeeding to explain it; primary ovarian insufficiency and other treatable causes need assessment.
• You have been trying to conceive for twelve months, or six months if you are over 35, or sooner if you have a known condition such as endometriosis, PCOS, previous pelvic surgery or cancer treatment.
• A home test or mail-order panel has returned a high FSH, a low AMH or a result you do not understand; the number needs cycle-day context, estradiol and often an ultrasound before it means anything.
• You are planning egg freezing or IVF and want reserve markers interpreted together.
• Menopausal symptoms are affecting sleep, mood, work or relationships, at any age; the diagnosis rests on symptoms and history, and treatment options exist.

Seek urgent care, the same day, for red-flag signs that are not about reserve but can accompany gynecologic or endocrine problems: sudden severe pelvic pain, heavy bleeding soaking a pad or tampon every hour for several hours, fainting, fever with pelvic pain, a positive pregnancy test with one-sided pain or shoulder-tip pain, new persistent headaches with vision change or milky nipple discharge, or symptoms of thyroid imbalance such as a racing heart with weight loss.

Every decision that follows a test, whether to repeat it, to add AMH or an antral follicle count, to start or stop a hormonal medicine, or to pursue fertility treatment, belongs to the clinician who knows your history. The role of an article like this is to make that appointment more productive, not to replace it.

Frequently asked questions

What does FSH stand for and what does the FSH test show?

FSH stands for follicle-stimulating hormone, a pituitary hormone that prompts ovarian follicles to grow each cycle. The blood test shows how much of it is circulating on the day of the draw. In early-cycle samples a higher level suggests the ovaries need more stimulation and reserve may be lower; in someone with absent periods it helps distinguish an ovarian cause from a brain or pituitary cause.

When should FSH be tested for fertility?

For ovarian reserve, FSH is usually tested on day 2, 3 or 4 of the menstrual cycle, with estradiol measured from the same sample. That window captures the pituitary’s baseline effort before a growing follicle suppresses the hormone. If cycles are irregular, a clinician may test on the first available day or use AMH and antral follicle count, which are far less dependent on timing.

What are normal FSH levels during perimenopause?

There is no single normal value. During perimenopause FSH often drifts into the teens or 20s IU/L but fluctuates widely, sometimes returning to the premenopausal range in a cycle where a healthy follicle grows. Mainstream guidance therefore diagnoses perimenopause from age, symptoms and menstrual pattern, using hormone tests selectively. After menopause FSH stays consistently high, commonly above 25 to 30 IU/L.

How can high FSH levels be treated in females?

High FSH itself is not treated, because it is a signal of reduced ovarian feedback rather than a disease, and no medicine restores lost follicles. Clinicians address the underlying goal: fertility treatment tailored to a lower expected response, or donor eggs when reserve is very low; hormone replacement to manage symptoms and protect bone in primary ovarian insufficiency; symptom-focused care in perimenopause. Every option is a prescribing decision.

What is an antral follicle count and what is a good number?

An antral follicle count is a transvaginal ultrasound tally of small resting follicles, roughly 2 to 10 millimetres, in both ovaries, usually done early in the cycle. Counts in the teens are typical; totals below about 5 to 7 suggest low reserve and a likely poor response to stimulation, and counts above roughly 20 to 25 raise the possibility of polycystic ovaries. Exact cut-offs vary between clinics.

Is the FSH test or AMH better for checking ovarian reserve?

AMH is generally the better single blood marker for predicting how many eggs the ovaries will produce in a treatment cycle, and antral follicle count performs about as well. FSH rises later in the decline and varies between cycles. FSH remains the key test for menopause and primary ovarian insufficiency, so the tests complement rather than replace one another, and clinicians usually read them together.

Can you get pregnant naturally with high FSH?

Yes, natural conception can and does occur with a raised FSH. The hormone describes how many follicles are available, not whether a healthy egg will ovulate in a given month. A prospective study of women aged 30 to 44 found raised FSH did not reduce the chance of conceiving over a year. High FSH does, however, make fertility treatment harder, which is why clinicians use it in planning.

Does hormonal contraception affect FSH and antral follicle count?

It does. Combined pills, patches and rings suppress FSH, lower AMH and reduce the number of visible antral follicles, so results taken while using them reflect the medication rather than the ovary. Clinicians may suggest testing after a washout period or rely on other information. Any decision to pause a prescribed contraceptive for testing should be made with the prescriber, not independently.

Can a home urine FSH test diagnose menopause?

No. A home strip detects FSH above a set threshold on the day of testing. Because FSH rises and falls unpredictably during perimenopause, a positive strip can be followed by a normal one, and ovulation and pregnancy remain possible. Menopause is confirmed twelve months after the final period; for women under 45, a clinician may use repeated blood FSH tests alongside symptoms and history.

Why would a doctor order an FSH test in men?

In men, FSH supports sperm production in the testes, so the test is ordered when a semen analysis shows a low or absent sperm count or when puberty is delayed. A high FSH suggests the testes are not responding well; a low FSH points toward the pituitary or hypothalamus. Timing does not matter in men, and the result is interpreted with testosterone and LH.

References

• MedlinePlus: Follicle-Stimulating Hormone (FSH) Levels Test
• Cleveland Clinic: Follicle-Stimulating Hormone (FSH)
• NHS: Infertility, Diagnosis

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.